Why the study?
Does the CYP2C19 681A allele increase clopidogrel resistance and adverse cardiovascular events in ACS patients undergoing PCI?
Population
110 patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI)
Comparison
CYP2C19 681A allele genotype vs CYP2C19 681GG genotype
Design
Cohort
Follow-up
12 months
Authors
Loading...
May identify clopidogrel-resistant ACS patients; leaves open whether CYP2C19 testing improves outcomes.
Does the CYP2C19 681A allele increase clopidogrel resistance and adverse cardiovascular events in ACS patients undergoing PCI?
The CYP2C19*2 polymorphism is associated with reduced clopidogrel antiplatelet activity and a higher incidence of adverse cardiovascular events in ACS patients undergoing PCI.
Wei et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: